This article we can explore the possibility of Supriya Lifescience Ltd as a multibagger 2022 Stock based on Value Investing principles.
About Supriya Lifescience Ltd
Supriya Lifescience Ltd. is a cGMP compliant API Manufacturing Organization with leadership position across key and niche products. Supriya Lifescience Ltd. has a well-established presence in API Manufacturing with focus in products of various therapeutic segments like – Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, Anti- Asthmatics etc.
They take pride in setting the products, processes and the systems as per the industry standards and in making continuous improvement to deliver quality products. Their facility is spread across an area of 47,000 sq.m. with delineated areas for warehouse, QA, QC, R & D, production and finished products (dedicated blocks for different therapeutic segments). The plant has current capacity of 550 KL and supported with multiple clean rooms for finished products. As a part of our capacity expansion plan, our capacity would be approximately 1000+ KL by 2024.
Backed by strong R&D, 14 active USDMFs, 8 active CEPs & World wide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. Company focus is to develop APIs and Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.
Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Their state-of-the-art facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. Facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.
The company was founded by Dr. Satish Wagh, a first generation entrepreneur and technocrat. Armed with technical knowledge, business acumen and an extensive experience of more than 35 years in the pharmaceutical industry, he has been instrumental for what Supriya Lifescience is today.
Supriya Lifescience Ltd. has a global footprint that extends across 86 countries. They diverse repertoire of Active Pharmaceutical Ingredients includes over 38 products that enjoy the implicit trust of a loyal global clientele. The company meet the most demanding quality standards and are registered in over 35 countries.
Products & Services
- Anti- Histamine
- Xanthine Derivatives
Profit & loss
Warren Buffett Checklist
- Company is NOT full contract player, But have own manufacturing facility
- Company is into Capacity Expansions in India, Japan & Korea
- Company have Good CAGR 30% above in Revenue & Profits
- Company is Zero Debt
- Good Promoters
- Good ROE, ROCE
- Current Valuation is moderately High
- Intrinsic Value Discount stands at 40% levels
- Debtor Days increasing
As per the Expansion & Value Investing grounds the company is having Multibagger Properties.
Supriya Lifescience have Multibagger properties.
Logos are Copyright of respective owners. The advice or opinions here is not for public distribution and has been furnished to you solely for your information purpose and must not be reproduced or redistributed to any other person. Any report is created from Public Source of Information available through Internet from Company website & Other websites & the Research Analyst does not guarantee the Validation of Content in this report.
FREE Multibagger India 2023
Multibagger with Expansion Plans | Low PE Ratio | Low Book Value Ratio | Intrinsic Value Discount 70 % | PLUS Free Value Investing Education